Exelixis (EXEL) Nyanmɛn Kpɛn
Nɛnɛn kpanlan$58.18Kpɛn 25 Sep 2026 19:59 UTC
Chɛ̀ndʒ+0.41%
AI bɛ́nɛ́nɛ́: EXEL
AI bɛ sɔhɛn sɛn na ɛbɛ yɛ a ɛwɔ nna a ɛdi akyi, nnwɔtwe no awieeɛ ne bosome no awieeɛ. Nsakraeɛ no yɛ nea wɔhwɛ firi sika a ɛwɔ hɔ seesei. Eyinom yɛ nkyɛmu nhyehyɛeɛ, ɛnyɛ nkyɛmu a wɔde bɛyɛ adwuma.
Prix su les 6 mois derniers
Premium ɛn nyɛ AI sika tɔnɔw 1 da, 1 kɛsɛli kɛn 1 bɛn fɔlɔ ni sika tɔnɔw a ni ahunye bɛɛ.
Yɛ́lɛ́ Premium🔒 Nzɛnkan nyinmɛn
Kpɛnɛn nyanmiɛn su lɛlɛ su — kpɛnɛn nyanmiɛn su lɛlɛ kun'n su, su'n su kpɛnɛn su lɛlɛ kun'n su — yɛ Premium su.
Yɛ́lɛ́ PremiumNyanmiɛn nɛnɛn
Exelixis, Inc. is a biotechnology company specializing in the development of promising small-molecule drugs for the treatment of cancer and other serious diseases, including kidney disease, thyroid cancer, and advanced melanoma. The company also establishes strategic partnerships with other pharmaceutical and biotechnology firms.
